RASAGILINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H13N.ClH
Molecular Weight	207.699
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.C#CCN[C@@H]1CCC2=CC=CC=C12

InChI

InChIKey=SROCRRNUGWYRHJ-UTONKHPSSA-N

InChI=1S/C12H13N.ClH/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;/h1,3-6,12-13H,7-9H2;1H/t12-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C12H13N
Molecular Weight	171.2383
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	( + )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18488080

Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor, which has been developed as an anti-Parkinson drug and was sold as a mesylate salt under brand name AZILECT. AZILECT is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD) as initial monotherapy and as adjunct therapy to levodopa. The effectiveness of AZILECT was demonstrated in patients with early Parkinson’s disease who were receiving AZILECT as monotherapy and who were not receiving any concomitant dopaminergic therapy. The effectiveness of AZILECT as adjunct therapy was demonstrated in patients with Parkinson’s disease who were treated with levodopa. PD is a progressive neurodegenerative, dopamine deficiency disorder. The main therapeutic strategies for PD treatment relies on dopamine precursors (levodopa), inhibition of dopamine metabolism (monoamine oxidase [MAO] B and catechol-O-methyl transferase inhibitors), and dopamine receptor agonists. In contrast to selegiline, rasagiline is not metabolized to potentially toxic amphetamine metabolites. The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Monoamine oxidase B 72 Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19673610	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Idiopathic Parkinson's disease 19 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf	Primary		Approved 8429	AZILECT Approved Use AZILECT (rasagiline tablets) is indicated for the treatment of Parkinson’s disease (PD). AZILECT, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease (1) Launch Date 2006

C_max

Value	Dose	Co-administered	Analyte	Population
56.13 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15628826	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RASAGILINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
53.53 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15628826	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RASAGILINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15628826	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RASAGILINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
2.5 mg single, transdermal Dose: 2.5 mg Route: transdermal Route: single Dose: 2.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/29159774	healthy, 22–25 years n = 4 Health Status: healthy Age Group: 22–25 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/29159774	Sources: https://pubmed.ncbi.nlm.nih.gov/29159774
2 mg single, oral Highest studied dose Dose: 2 mg Route: oral Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30218626	healthy, 33 years n = 16 Health Status: healthy Age Group: 33 years Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/30218626	Sources: https://pubmed.ncbi.nlm.nih.gov/30218626
2 mg 1 times / day steady, oral Highest studied dose Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30218626	healthy, 33 years n = 16 Health Status: healthy Age Group: 33 years Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/30218626	Other AEs: Ear discomfort, Musculoskeletal pain... Other AEs: Ear discomfort (1 patient) Musculoskeletal pain (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/30218626
4 mg 1 times / day steady, oral Highest studied dose Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15300656	unhealthy, 62.0 years n = 14 Health Status: unhealthy Condition: Early Parkinson’s Disease Age Group: 62.0 years Sex: M+F Population Size: 14 Sources: https://pubmed.ncbi.nlm.nih.gov/15300656	Sources: https://pubmed.ncbi.nlm.nih.gov/15300656
100 mg single, oral Overdose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	unknown, adult n = 1 Health Status: unknown Age Group: adult Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	Other AEs: Serotonin syndrome... Other AEs: Serotonin syndrome (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf
3 mg 1 times / day multiple, oral Overdose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	unknown, adult n = 1 Health Status: unknown Age Group: adult Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	Other AEs: Hypertension, Orthostatic hypotension... Other AEs: Hypertension (1 patient) Orthostatic hypotension (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf
1 mg 1 times / day steady, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: steady Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	unhealthy, adult n = 149 Health Status: unhealthy Condition: Parkinson’s disease Age Group: adult Population Size: 149 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	Disc. AE: Hallucinations... AEs leading to discontinuation/dose reduction: Hallucinations Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf

AEs

AE	Significance	Dose	Population
Ear discomfort	1 patient	2 mg 1 times / day steady, oral Highest studied dose Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30218626	healthy, 33 years n = 16 Health Status: healthy Age Group: 33 years Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/30218626
Musculoskeletal pain	1 patient	2 mg 1 times / day steady, oral Highest studied dose Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30218626	healthy, 33 years n = 16 Health Status: healthy Age Group: 33 years Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/30218626
Serotonin syndrome	1 patient	100 mg single, oral Overdose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	unknown, adult n = 1 Health Status: unknown Age Group: adult Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf
Hypertension	1 patient	3 mg 1 times / day multiple, oral Overdose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	unknown, adult n = 1 Health Status: unknown Age Group: adult Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf
Orthostatic hypotension	1 patient	3 mg 1 times / day multiple, oral Overdose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	unknown, adult n = 1 Health Status: unknown Age Group: adult Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf
Hallucinations	Disc. AE	1 mg 1 times / day steady, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: steady Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	unhealthy, adult n = 149 Health Status: unhealthy Condition: Parkinson’s disease Age Group: adult Population Size: 149 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 CYP4A 19	CYP1A2 1054 P-gp 1537 CYP2A6 543

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no
CYP4A 33	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 57, 95	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 56, 57, 69	major	yes (co-administration study) Comment: ciprofloxacin increased rasagiline AUC by 83% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 56, 57, 69
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_ClinPharmR.pdf Page: 97.0	no
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/26530401/	no	no (co-administration study) Comment: hesperetin and narigenin enhanced the systemic exposure of rasagiline not through P-gp Sources: https://pubmed.ncbi.nlm.nih.gov/26530401/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_Azilect_PharmR.pdf Page: 265.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63620	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63620
ChemicalBook	CB2459598	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2459598
MolPort	MolPort-003-850-132	https://www.molport.com/shop/molecule-link/MolPort-003-850-132
ZINC	ZINC000019875504	http://zinc15.docking.org/substances/ZINC000019875504
eMolecules	2727012	https://www.emolecules.com/cgi-bin/more?vid=2727012

PubMed

Title	Date	PubMed
Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.	2003 Apr	12943198
Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity.	2003 Nov 17	14612913
The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.	2003 Oct 15	14555244
L-DOPA increases noradrenaline turnover in central and peripheral nervous systems.	2003 Sep	12907313
Recent approaches to novel anti-Alzheimer therapy.	2004	15544506
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.	2004 Apr	15096406
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.	2004 Aug	15300656
Clinical applications of MAO-inhibitors.	2004 Aug	15279566
Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.	2004 Jan	14697899
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?	2004 Jan	14696044
Drugs in development for Parkinson's disease.	2004 Jul	15298067
Neuroprotection in Parkinson's disease: an elusive goal.	2004 Jul	15217541
Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.	2004 Jul	15165835
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.	2004 Jun	15147504
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.	2004 Jun	15144871
Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.	2004 Mar 25	15027867
N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.	2004 May	14687604
[Are there innovations in the treatment of Parkinson's disease?].	2004 Nov 3	15571301
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.	2004 Oct	15339864
Clinical trials of neuroprotection for Parkinson's disease.	2004 Oct 12	15477583
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.	2004 Oct 12	15477581
[The early therapy challenge].	2005	16515310
Alternatives to levodopa in the initial treatment of early Parkinson's disease.	2005	16156677
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.	2005	15822111
Rasagiline.	2005	15663351
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.	2005 Apr	15850677
Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.	2005 Aug	16179541
Reexamination of the TEMPO Study.	2005 Aug	16087778
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.	2005 Aug	16027398
Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.	2005 Dec 29	16366596
[Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].	2005 Jul	16038119
Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells.	2005 Mar	15721173
Present and future drug treatment for Parkinson's disease.	2005 Nov	16227533
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine.	2005 Nov	16148027
Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons.	2005 Nov 25	16226724
In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.	2005 Oct	16204711
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.	2005 Oct	16181413
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.	2005 Oct	16086033
[Rasagiline in motor fluctuations].	2005 Sep	16217881
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?	2005 Summer	16007239
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.	2006 Apr	16569799
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.	2006 Apr 11	16606909
Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.	2006 Feb	16451296
Rasagiline -- is there a place for this drug in managing Parkinson's disease?	2006 Feb	16451281
Drugs in development for Parkinson's disease: an update.	2006 Jan	16425668
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.	2006 Jan	16402116
Rasagiline improves quality of life in patients with early Parkinson's disease.	2006 May	16450340
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.	2006 May 15	16675649
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.	2006 May 23	16717254
Safety of rasagiline in elderly patients with Parkinson disease.	2006 May 9	16682679

Patents

Sample Use Guides

In Vivo Use Guide

Monotherapy: the recommended AZILECT (RASAGILINE MESYLATE) dose for the treatment of Parkinson’s disease patients is 1 mg administered once daily. Adjunctive Therapy: the recommended initial dose is 0.5 mg administered once daily. If a sufficient clinical response is not achieved, the dose may be increased to 1 mg administered once daily. Change of levodopa dose in adjunct therapy: When AZILECT is used in combination with levodopa, a reduction of the levodopa dosage may be considered based upon individual response. During the controlled trials of AZILECT as adjunct therapy to levodopa, levodopa dosage was reduced in some patients. In clinical studies, dosage reduction of levodopa was allowed within the first 6 weeks if dopaminergic side effects, including dyskinesia and hallucinations, emerged.

Route of Administration: Oral

In Vitro Use Guide

The present series of in vitro experiments using the rat hippocampal slice preparation deals with effects of rasagiline and its metabolite R-(-)-aminoindan on the pyramidal cell response after electric stimulation of the Schaffer Collaterals in comparison to selegiline, another MAO B inhibitor. During the first series, this response was attenuated in the presence of rasagiline and aminoindan-to a lesser degree of selegiline-in a concentration dependent manner (5-50 μM) after single stimuli as well as under theta burst stimulation (TBS). The presence of rasagiline and aminoindan, but rarely the presence of selegiline, prevented this break down. Following glutamate receptor mediated enhancements of neuronal transmission in a second series of experiments very clear differences could be observed in comparison to the action of selegiline: NMDA receptor, AMPA receptor as well as metabotropic glutamate receptor mediated increases of transmission were concentration dependently (0,3 - 2 μM) antagonized by rasagiline and aminoindan, but not by selegiline. On the opposite, only selegiline attenuated kainate receptor mediated increases of excitability. Thus, both monoamino oxidase (MAO) B inhibitors show attenuation of glutamatergic transmission in the hippocampus but interfere with different receptor mediated excitatory modulations at low concentrations.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:09:40 GMT 2023` Edited by `admin` on `Fri Dec 15 18:09:40 GMT 2023`
Record UNII	2V1ZE3067R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RASAGILINE HYDROCHLORIDE

Common Name

English

1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-, HYDROCHLORIDE, (R)-

Systematic Name

English

1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYN-1-YL-, HYDROCHLORIDE (1:1), (1R)-

Common Name

English

(R)-(+)-N-PROPARGYL-1-AMINOINDAN HYDROCHLORIDE

Systematic Name

English

1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-, HYDROCHLORIDE, (1R)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

9794292

Created by admin on Fri Dec 15 18:09:40 GMT 2023 , Edited by admin on Fri Dec 15 18:09:40 GMT 2023

PRIMARY

CAS

136236-50-5

Created by admin on Fri Dec 15 18:09:40 GMT 2023 , Edited by admin on Fri Dec 15 18:09:40 GMT 2023

PRIMARY

FDA UNII

2V1ZE3067R

Created by admin on Fri Dec 15 18:09:40 GMT 2023 , Edited by admin on Fri Dec 15 18:09:40 GMT 2023

PRIMARY

MESH

C031967

Created by admin on Fri Dec 15 18:09:40 GMT 2023 , Edited by admin on Fri Dec 15 18:09:40 GMT 2023

PRIMARY

Related Record Type Details


					003N66TS6T

RASAGILINE

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					003N66TS6T

RASAGILINE

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18488080

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18488080

C_max

T_1/2

Drug as perpetrator